Darzalex 400 mg/20 ml Concentrate Solution for Infusion is a groundbreaking monoclonal antibody therapy containing Daratumumab, developed by Janssen Pharmaceuticals. This advanced biologic treatment has revolutionized the management of multiple myeloma, a complex and often aggressive blood cancer. Darzalex is a targeted anti-CD38 monoclonal antibody that works by harnessing the immune system to fight and destroy cancer cells. Used alone or in combination with other therapies, Darzalex has demonstrated remarkable efficacy in improving progression-free survival and overall response rates in patients with relapsed, refractory, or newly diagnosed multiple myeloma.
Key Product Details:
- Active Ingredient: Daratumumab 400 mg/20 ml
- Form: Concentrate Solution for Infusion
- Administration: Intravenous (IV) infusion
- Packaging: 1 Vial (20 ml solution containing 400 mg Daratumumab)
- Manufacturer: Janssen Pharmaceuticals (Johnson & Johnson)
Benefits of Darzalex 400 mg/20 ml:
- Targeted Immunotherapy: Darzalex specifically targets CD38, a protein abundantly expressed on the surface of multiple myeloma cells. By binding to CD38, Daratumumab triggers direct tumor cell death while also recruiting the immune system to attack cancer cells.
- Combination Therapy: Darzalex is often combined with other anti-myeloma agents such as Lenalidomide (Revlimid), Bortezomib (Velcade), or Dexamethasone for synergistic effects, improving treatment response and patient outcomes.
- Proven Efficacy: Clinical trials have shown that Darzalex significantly prolongs progression-free survival and overall survival, particularly in patients with relapsed or refractory multiple myeloma.
- Minimal Tumor Burden Approach: Effective in patients who have previously received multiple lines of therapy, as well as newly diagnosed patients ineligible for stem cell transplantation.
- Rapid Symptom Relief: Many patients experience improvements in bone pain, fatigue, and anemia symptoms early during the treatment cycle.
Indications and Approved Uses:
- Relapsed or Refractory Multiple Myeloma (RRMM): Used as monotherapy or in combination with standard therapies.
- Newly Diagnosed Multiple Myeloma: Suitable for patients ineligible for autologous stem cell transplantation (ASCT).
- Maintenance Therapy: Utilized for long-term disease control after achieving remission.
How Does Darzalex Work?
Darzalex (Daratumumab) is a first-in-class human monoclonal antibody that binds to CD38, a glycoprotein expressed on multiple myeloma cells. Upon binding, Darzalex induces tumor cell death through various mechanisms:
- Direct Cytotoxicity: Inducing apoptosis and cell lysis.
- Complement-Dependent Cytotoxicity (CDC): Activating the complement cascade leading to cancer cell destruction.
- Antibody-Dependent Cellular Cytotoxicity (ADCC): Recruiting natural killer (NK) cells and macrophages to attack myeloma cells.
- Immunomodulation: Reducing CD38-positive regulatory cells, enhancing T-cell and natural killer cell activity against the tumor.
Dosage and Administration:
- Initial Dose: 16 mg/kg intravenously (IV) over several hours due to the risk of infusion-related reactions.
- Subsequent Doses: Administered weekly, every two weeks, or monthly, depending on the treatment phase and response.
- Premedication Required: Patients are premedicated with corticosteroids, antihistamines, and antipyretics to minimize infusion reactions.
Important Safety Information:
- Infusion Reactions: Common during the first infusion, presenting as cough, chills, shortness of breath, or nausea. Typically managed with premedication and slowing infusion rates.
- Infections: Risk of upper respiratory tract infections, pneumonia, and herpes zoster reactivation. Prophylactic antiviral therapy is often recommended.
- Hematological Toxicity: Risk of anemia, thrombocytopenia, and neutropenia. Regular blood monitoring is essential.
- Interference with Blood Typing: Darzalex can bind to red blood cells, affecting indirect antiglobulin tests (Coombs test). Blood typing should be done before starting therapy.
- Contraindications: Not recommended for patients with severe hypersensitivity to Daratumumab or any of its components.
Storage Instructions:
- Temperature: Store between 2°C to 8°C (36°F to 46°F).
- Do Not Freeze: Keep the vial in the original packaging to protect from light.
Why Choose Darzalex 400 mg/20 ml?
- Clinically Proven Survival Benefit: Patients treated with Darzalex have shown a remarkable extension in survival compared to standard therapy alone.
- Leading Immunotherapy in Multiple Myeloma: Trusted and widely used globally as part of standard treatment protocols.
- Enhanced Quality of Life: Reduces disease burden and improves symptoms such as bone pain, fatigue, and anemia.
- Flexible Treatment Regimens: Compatible with other multiple myeloma treatments, allowing for tailored therapy based on individual patient needs.
Clinical Trial Highlights:
- POLLUX Trial: Darzalex + Lenalidomide + Dexamethasone demonstrated 63% reduction in disease progression risk compared to Lenalidomide + Dexamethasone alone.
- CASTOR Trial: Darzalex + Bortezomib + Dexamethasone showed 61% reduction in disease progression risk compared to Bortezomib + Dexamethasone alone.
Buy Darzalex 400 mg/20 ml Online:
Looking to buy Darzalex 400 mg Daratumumab concentrate infusion vials online? We offer authentic Janssen Darzalex with global shipping options. Secure your order today and access cutting-edge immunotherapy for multiple myeloma treatment.
Darzalex 400 mg – Empowering Myeloma Patients with Advanced Immunotherapy
Choosing Darzalex (Daratumumab) is choosing hope, precision, and enhanced survival. This monoclonal antibody is setting new standards in multiple myeloma treatment, giving patients longer, healthier lives.
Değerlendirmeler
Henüz değerlendirme yapılmadı.